Carrie K. Jones

Allen Institute for Brain Science — United States

Neuroscience · Life Sciences

52h-index8.5kcitations271works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(147), Receptor Mechanisms and Signaling(143), Pharmacological Receptor Mechanisms and Effects(35), Nicotinic Acetylcholine Receptors Study(34), Ion channel regulation and function(28)

Publications271 total

Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2
Journal of Medicinal Chemistry·2026Open Access
Discovery of VU6052254: A Novel, Potent M <sub>1</sub> Positive Allosteric Modulator
ACS Chemical Neuroscience·2025Open Access
Optimization of Selective and CNS Penetrant Alkyne-Based TREK Inhibitors: The Discovery and Characterization of ONO-9517601 (VU6022856) and ONO-7927846 (VU6024391)
Journal of Medicinal Chemistry·2025Open Access
Highly Potent and Subtype-Selective Sperm-Specific Potassium Channel SLO3 Inhibitors Display High Tissue Exposure in the Murine Female Reproductive Tract
ACS Pharmacology & Translational Science·2025Open Access
653. THE DEVELOPMENT OF DRUGS TO ACTIVATE THE MUSCARINIC M1 AND M4 RECEPTORS TO TREAT DISORDERS OF THE HUMAN CNS
The International Journal of Neuropsychopharmacology·2025Open Access
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants
Alzheimer s Research & Therapy·2025· 2 citedOpen Access
Discovery of a Novel sp<sup>3</sup>-Rich M<sub>1</sub> Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping
ACS Medicinal Chemistry Letters·2025· 1 citedOpen Access
Discovery of Pre-Clinical Candidate <b>VU6008055</b>/<b>AF98943</b>: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy
ACS Chemical Neuroscience·2025· 2 citedOpen Access
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer’s disease: A Single Ascending-Dose Study in Healthy Participants
2025Open Access
Shank3 modulates Rpl3 expression and protein synthesis via mGlu5: implications for Phelan McDermid syndrome
Molecular Psychiatry·2025· 5 citedOpen Access
Astrocytes expressing M <sub>4</sub> muscarinic acetylcholine receptor regulate locomotion and survival in murine prion disease
2025
Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical Trials
ACS Chemical Neuroscience·2024· 9 citedOpen Access
Discovery of 4-(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5
ACS Medicinal Chemistry Letters·2024· 2 citedOpen Access
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)
ACS Chemical Neuroscience·2024· 3 citedOpen Access
Development of VU6036864: A Triazolopyridine-Based High-Quality Antagonist Tool Compound of the M<sub>5</sub> Muscarinic Acetylcholine Receptor
Journal of Medicinal Chemistry·2024· 4 citedOpen Access
Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists
ACS Medicinal Chemistry Letters·2024· 6 citedOpen Access
Development of Potent and Selective Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 2 for the Potential Treatment of Alzheimer’s Disease
Alzheimer s & Dementia·2023· 3 citedOpen Access
The M<sub>4</sub> muscarinic acetylcholine receptor positive allosteric modulator VU0467154 normalizes non‐rapid eye movement sleep deficits in non‐pathologically aged mice.
Alzheimer s & Dementia·2023· 1 citedOpen Access
M <sub>1</sub> -selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primates
Proceedings of the National Academy of Sciences·2023· 21 citedOpen Access
Decreased expression of ribosomal protein Rpl3 contributes to behavioral deficits caused by Shank3 deficiency
Research Square (Research Square)·2023Open Access
page 1 of 14Next →

Frequent Co-authors

P. Jeffrey Conn(38), Craig W. Lindsley(37), Colleen M. Niswender(25), J. Scott Daniels(16), Zixiu Xiang(15), Thomas M. Bridges(14), Michael Bubser(13), Jerri M. Rook(11), Analisa D. Thompson(9), C. David Weaver(8), Nellie Byun(7), Satyawan Jadhav(7), Alice L. Rodriguez(7), Shaun R. Stauffer(7), Ryan D. Morrison(7), Anna L. Blobaum(7), Corey R. Hopkins(7), Harlan E. Shannon(6), Meredith J. Noetzel(6), Michael R. Wood(6)